Suppliers and packagers for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms Co	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	209721	ANDA	Amneal Pharmaceuticals NY LLC	60219-2095-3	30 TABLET, FILM COATED in 1 BOTTLE (60219-2095-3)	2018-08-26
Amneal Pharms Co	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	209721	ANDA	Amneal Pharmaceuticals NY LLC	69238-2092-3	30 TABLET, FILM COATED in 1 BOTTLE (69238-2092-3)	2018-08-26
Amneal Pharms Co	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	209721	ANDA	Amneal Pharmaceuticals NY LLC	69238-2093-3	30 TABLET, FILM COATED in 1 BOTTLE (69238-2093-3)	2018-08-26

Executive summary

Last updated: May 27, 2026

• Emtricitabine and tenofovir disoproxil fumarate (TDF, co-packaged as Truvada and generic equivalents) are supplied globally through a layered vendor stack: (1) API and key intermediates, (2) formulation/tablet manufacturing, (3) bottle/blister packaging, and (4) cold-chain is generally not required for these small molecules.
• The most visible “supplier” relationships in public channels are concentrated among large CDMOs and API producers with FDA-inspected manufacturing sites and established commercial manufacturing footprints for HIV antiretrovirals.
• This analysis focuses on the typical supplier categories and the industry-standard manufacturing sources used to support FDA commercialization of emtricitabine + TDF tablets; it does not map every upstream intermediate supplier because those are not consistently disclosed in regulator-facing or patent-facing documents.

What suppliers make emtricitabine and tenofovir disoproxil fumarate APIs for FDA commercial use?

Who are the typical API suppliers for emtricitabine (FTC) used in fixed-dose combinations

Publicly visible supply chains for emtricitabine generally fall into two groups: (a) API manufacturers with FDA drug substance registrations and (b) API distributors that broker lots into downstream tablet CDMOs or MAH supply chains.

Commonly encountered supplier profiles in this category

• Integrated API producers of nucleoside reverse transcriptase inhibitor (NRTI) actives, often with multiple line capabilities for final purification, polymorph control, and solvent-residue control.
• Specialty API makers supplying emtricitabine API and/or key intermediates under commercial GMP contracts to generic tablet manufacturers and CDMOs.

Who are the typical API suppliers for tenofovir disoproxil fumarate (TDF) used in fixed-dose combinations

Tenofovir disoproxil fumarate supply is usually anchored by manufacturers with established fermentation chemistry upstream and tightly controlled esterification and salt-formation steps downstream.

Supplier profiles

• Large-scale API manufacturers with capability for disoproxil ester synthesis, controlled reaction workup, and fumarate salt formation.
• CDMO/API hybrid providers that produce API, then ship to formulation sites for tableting and coating.

How are emtricitabine and TDF APIs typically sourced

Most branded and generic tablet supply chains do not “single-source” both actives from one vendor. A common structure is:

• Separate API sourcing for FTC and TDF, with at least two qualified vendors per active for supply continuity.
• Lot release conducted through either the MAH’s quality system or the tablet CDMO’s incoming testing and compliance documentation package.

Which companies manufacture emtricitabine/tenofovir disoproxil fumarate tablets for Truvada and generics?

What CDMOs or tablet manufacturers appear in the FTC/TDF tablet supply chain

Tablet manufacture for emtricitabine/TDF requires:

• blending and granulation with excipient systems stable to moisture and polymorph drift
• tight assay and impurity control
• coating and packaging under controlled humidity

Common manufacturer categories

• Multi-product oral solid dose CDMOs with dedicated lines for antiretrovirals.
• Generic tablet manufacturers producing commercial lots for ANDAs and label extensions.

What packaging suppliers are used for FTC/TDF

For oral tablets, packaging suppliers typically provide:

• HDPE bottles with induction seals and desiccant solutions where needed by the specific stability program
• OPA/Alu/PVC blister systems for market-specific labels and blister pack SKUs

Are cold-chain logistics required

No. Emtricitabine and TDF tablets are generally handled under standard ambient controlled conditions. Stability programs drive packaging specs rather than temperature-dependent logistics.

How do upstream suppliers of emtricitabine and tenofovir intermediates affect commercial supply?

Which intermediate supply constraints most often impact FTC/TDF availability

• Nucleoside intermediate bottlenecks in the FTC pathway
• Ester precursor supply and salt-formation step capacity in the TDF pathway
• Solvent and reagent qualification for GMP batch consistency
• Analytical method availability for impurity profiling (critical because NRTIs have process-related impurities)

What happens when an intermediate supplier’s capacity tightens

Downstream impacts tend to show up as:

• delayed API availability for tableting slots
• increased need for requalification and bridging lots
• higher safety stock to cover long lead times for nucleoside chemistry and esterification sequences

What does the FDA drug master file and supplier disclosure pattern look like for FTC/TDF?

How are suppliers documented to FDA for FTC/TDF

FTC/TDF supply documentation typically includes:

• API manufacturer identity in the drug substance section (e.g., DMF references or listed manufacturing sites depending on application format)
• tablet manufacturing site(s) listed in drug product sections
• quality agreements supporting cross-site release and testing

What “supplier” means in regulated submissions

In practice, “supplier” in regulatory terms can mean:

• drug substance manufacturer of record (DS-MF or DMF holder)
• drug product manufacturer of record (tablet site)
• testing site used for release or stability analytics

Where do FTC/TDF suppliers concentrate geographically?

API manufacturing footprint

FTC and TDF API manufacturing is concentrated in established global pharma-manufacturing geographies with FDA or EMA inspection track records, including:

• India
• China
• US and Europe for some product-specific intermediates or redundant supply

Tablet formulation and packaging footprint

Tablet formulation and packaging generally mirror the CDMO footprint used for generic oral solids:

• high-volume oral solid dose facilities in India/China and in the US/EU
• additional packaging houses supporting blister and bottle formats for different markets

How do suppliers differ for branded Truvada vs generic FTC/TDF?

Branded supply chain characteristics

Branded product supply chains usually:

• lock in API and formulation supply contracts with multi-year qualification cycles
• maintain redundant sources for continuity
• run tighter process development and impurity specifications aligned to branded stability and clinical history

Generic supply chain characteristics

Generic supply chains typically:

• use qualified API lots from approved vendors
• select CDMOs optimized for cost and scale
• manage regulatory expectations for impurity profiles through tighter in-process controls and finished product analytics

What supplier risks matter most for emtricitabine/TDF commercialization?

Quality and compliance risks

• microbial and endotoxin management for oral solids is less complex than injectables but still requires robust cleaning validation and environmental monitoring
• impurity control is critical for nucleoside analogs and ester-derived intermediates

Continuity and lead-time risks

• tenofovir disoproxil fumarate is chemistry-intensive and can carry longer lead times for consistent salt formation and impurity profiles
• API batch scheduling can bottleneck formulation slots

Regulatory inspection risks

• manufacturer-of-record inspection outcomes can affect product continuity
• changes in manufacturing site, process, or control strategy trigger comparability work and regulatory updates

Key supplier categories checklist (actionable)

Use this structure when building a supplier map for emtricitabine + TDF tablets:

1. FTC API supplier (drug substance manufacturer of record and any DMF references)
2. TDF API supplier (drug substance manufacturer of record and any DMF references)
3. Key intermediate suppliers (only where disclosed through quality agreement requirements or audit reports)
4. Tablet formulation/manufacturing site (blending, granulation, tableting, coating)
5. In-process and release testing labs (quality control sites)
6. Packaging suppliers (bottle and blister lines)
7. Stability testing partner (internal or contract lab)

Key Takeaways

• FTC/TDF supply is typically multi-tier: separate FTC and TDF API sources, one or more tablet CDMOs/manufacturers, then packaging partners for bottles and blisters.
• The biggest operational supplier risks cluster around (a) nucleoside intermediate and (b) TDF ester precursor and salt formation capacity, plus impurity analytics and GMP inspection outcomes.
• For procurement and diligence, map suppliers at the FDA “maker of record” level: drug substance and drug product sites, plus testing/packaging where quality agreements assign responsibility.

FAQs

1. What does FDA regulatory “supplier” mean for emtricitabine/tenofovir disoproxil fumarate products?
2. Do emtricitabine and TDF tablets require special storage temperature controls in distribution?
3. What are the most common technical reasons for API batch rejection in FTC/TDF supply chains?
4. How do formulation and packaging material choices affect FTC/TDF tablet stability?
5. What supplier continuity strategies are typically used to prevent shortages of emtricitabine/TDF APIs?

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
3. European Medicines Agency. (n.d.). Medicine information and EPARs. https://www.ema.europa.eu/